Sign In

Pablo Lubroth

Hummingbird Ventures

Pablo Lubroth is a prominent figure investing in early-stage science and actively contributing through his writing at decodingbio.com. With a comprehensive educational background, he holds degrees including an MPhil in Bioscience Enterprise from the University of Cambridge, an MSc in Biochemical Engineering, and a BSc in Pharmacology and Neuroscience from UCL. He also pursued studies at Runnymede College.

Throughout his career, Pablo has been associated with various organizations, showcasing his diverse skills and interests. He was a Co-Founder at Decoding Bio, an Investor at Hummingbird Ventures and Future Planet Capital, a Corporate Development Associate at Horizon Discovery, and a Co-Founder at Hera Biotech. Additionally, he engaged in research roles at prestigious institutions like the University of Cambridge and UCL, demonstrating his strong research acumen and academic prowess.

Highlights

Jul 26 · linkedin

Decoding Bio’s AI x Bio Summit 2024 is a wrap! 300 attendees, 3 panels, 1 fireside chat, 13 roundtables later, we couldn’t be more energized about what is coming in the new generation of life science companies.

The Summit's mission is to foster meaningful conversations within the ecosystem, moving beyond the polarized debates. The field is marred with easy, extreme positions: “AI companies don’t understand biology” or “AI is a paradigm shift and is revolutionizing drug discovery”. The truth is that whilst these are extreme examples, they’re not bold or contrarian opinions; they’re the easy way out of a real conversation. It is clear that the answer is nuanced, and the Summit’s speakers and attendees demonstrated this.

Our hope is that, in the future, an AI x Bio Summit will no longer be necessary: that pharma executives, industry scientists, academia, startup founders and execs, late-stage and public equity investors and the venture ecosystem can seamlessly discuss how AI can better serve patients and the planet. To paraphrase Amit Etkin from Alto Neuroscience: "Hopefully, in the future, we won't need AI conferences, but simply conferences where we discuss patient outcomes."

The AI in Pharma panel with Greg Meyers (Bristol Myers Squibb), Cynthia Hong, (Novartis), Shameer Khader, (Sanofi) and Guang Yang, (McKinsey & Company) showcased how AI has permeated various departments due to its real utility. It demonstrated that pharmaceutical companies are not the innovation-averse incumbents as often perceived and have a defined vision for what they want to build, buy, or partner with. The Foundation Models in Biology panel with Tom Sercu (EvolutionaryScale), Philipp Lorenz (Basecamp Research), Matej Macak (QuantumBlack, AI by McKinsey), Ali Madani (Profluent) and Renee Y. (NVIDIA) discussed how new models are enabling us to design, rather than discover new biology. The Building a Biotech in 2024 panel with Sajith Wickramasekara (Benchling), Michael Nally (Generate:Biomedicines) and Bigyan Bista (Enveda Biosciences) showed us that it is critical to their businesses, but it won't replace wet lab experimentation anytime soon.

I wanted to thank the incredible co-hosts Amee Kapadia (Cantos) and Eric J. Dimise, & Johanna (Rodriguez) Grossman, (NYSE), our sponsors who made it possible (Amazon Web Services (AWS), Bunsen, HSBC, McKinsey & Company and Orrick, Herrington & Sutcliffe LLP), all the speakers and roundtable leads who generously offered their time and wisdom, as well as all the attendees that came for the day.

Until next year!

Jul 19 · linkedin

This week we cover the history of Regeneron in 350 words.

A memorable quote from its founder Leonard Schleifer on how they raised their first $1M: “I got to meet George and he struck me as a guy who actually did want to build something, who respected science, who really would let us run, who respected the fact that we had really smart people we were trying to bring around. And wasn't trying to be like a super ego venture capitalist like you find today, who think they know more about the science than anybody else, and they're going to decide what you work on. They're going to tell you how to do it. He wasn't that type of a guy. He was a very, very creative, helpful on the business side, super helpful and helping me understand some of these things. And he and I finally went to a Chinese restaurant and we literally scratched out a deal on the terms that he'd give me a million dollars on the back of a napkin”

See the full post in Decoding Bio's BioByte below

Pablo Lubroth
Add to my network

Location

New York, New York, United States